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CHAPTER 1 
 
 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Nociceptors. 
The nociceptor is a peripheral sensory neuron that detects noxious (painful) stimuli. A noxious 
stimulus is one with intensity and quantity of sufficient quality to cause reflex withdrawal, 
autonomic responses and pain (Sherrington, 1903). Nociceptors are primary sensory neurons that 
respond to high threshold stimuli (Woolf and Ma, 2007) and are described as having four 
functional parts: peripheral terminal, axon, cell body and central terminal (synapse; Diag. I). 
Peripheral sensory axons and terminals also are called peripheral or primary afferents. The 
neuronal cell bodies are found in peripheral ganglia, e.g., dorsal root and trigeminal ganglia, and 
the peripheral terminal lies in the target tissue (Woolf and Ma, 2007). The peripheral terminal 
transduces the external noxious stimulus and initiates an action potential, the axon conducts the 
action potential, whereas the cell body controls the identity and integrity of the entire neuron. The 
central terminal participates in the first synapse in the central nervous system (CNS) sensory 
pathway (Woolf and Ma, 2007). The sensitivity of both the peripheral terminal and central 
synapse can be altered to augment or diminish nociception. Augmented alterations of nociception 
at the peripheral terminal and central synapse are called peripheral and central sensitization, 
respectively. The initial background will focus on aspects common to all nociceptors followed 
later with a more detailed description of corneal nociceptors.  
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Trigeminal Ganglion Neuron for Corneal Sensory Innervation 
 
Diagram I. A trigeminal ganglion neuron for corneal sensory innervation. Schematic 
of a primary afferent neuron with its central terminal in the pons and medulla, the cell 
body in the trigeminal ganglion and a peripheral terminal that innervates the target tissue, 
e.g., cornea (adapted from Woolf and Ma, 2007). 
 
Nociception is initiated when nociceptive sensory fibers innervating peripheral tissues are 
activated by potential or ongoing noxious stimuli. This occurs because nociceptive sensory 
neurons express proteins that respond to specific noxious chemical, mechanical and/or thermal 
stimuli. These proteins are referred to as transducers (Caterina and Julius, 2001; Julius and 
Basbaum, 2001) and they respond only to specific, high threshold stimuli. Studies in the skin 
have shown the presence of a number of ion channels in peripheral sensory terminals that 
function as transducers of noxious temperature, chemical, and touch sensations (Suguiura et al., 
2002; Ferreira et al., 2004; Lumpkin and Caterina, 2007). Among these is the transient receptor 
potential (TRP) family of cation channels for response to chemical stimulation and noxious and 
innocuous temperatures. For noxious temperatures in skin, transient receptor potential vanilloid 1 
(TRPV1), a noxious heat transducer, responds in the nociceptive range of 46.5°C to 56°C 
(Caterina et al., 1997; Rau et al., 2007), and transient receptor potential melastatin 8 (TRPM8), a 
noxious cold transducer, responds to temperatures less than 15°C (Bautista et al., 2007). Transient 
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receptor potential l ankyrin 1 (TRPA1) also is a noxious cold transducer, responding to 
temperatures as low as 10°C (Karashimaa et al., 2008). Likewise in the cornea, TRPV1 and 
TRPM8 have been identified and described (Diag. II; Madrid et al., 2006, Murata and Masuko, 
2006, Mergler et al., 2010).  
 
The peripheral terminal of a nociceptor detects noxious or tissue damaging stimuli when the 
stimulus reaches a threshold to open the transducer ion channel (Woolf and Ma, 2007). An influx 
of calcium and sodium ions occurs that depolarizes the peripheral terminal membrane (Caterina et 
al., 1997; Mergler et al., 2010 ). Nociceptors express specific voltage gated sodium (Nav) ion 
channels, Nav1.7, 1.8 and 1.9, that produce action potentials for the conduction of nerve impulses 
(Djouhri et al., 2002; Djouhri et al., 2003; Priest et al., 2005). These transmembrane proteins 
transiently open to permit the rapid influx of sodium ions in response to membrane 
depolarization. Influx of sodium ions depolarizes the nociceptor axon membrane further 
generating an action potential that is propagated from the nociceptor peripheral terminal via the 
axon to the central nervous system (Woolf and Ma, 2007). 
 
With ongoing peripheral stimulation, influx of calcium ions into the peripheral terminal can 
trigger a number of intracellular signal transduction pathways. For example, activation of protein 
kinases in the peripheral terminal such as phosphatidylinositol 3-kinase (PI3K), protein kinase A 
(PKA) or protein kinase C (PKC) causes phosphorylation of proteins such as TRPV1 and sodium 
channels (Zou et al., 2000; Zou et al., 2002; Zhuang et al., 2004). When there is phosphorylation 
of TRPV1, the activation threshold is lowered thereby increasing the excitability of the nerve 
terminal. Also, phosphorylation of sodium channels reduces the resting potential of the membrane 
and further increases the excitability of the nerve terminal. The net effect forms the basis for 
peripheral sensitization leading to heightened sensitivity to innocuous (allodynia) and painful 
(hyperalgesia) stimuli. Peripheral sensitization, therefore, leads to increased action potentials 
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propagated along the axon toward the CNS (Woolf and Ma, 2007). 
 
 
Diagram II. Schematic of events that occur when a noxious stimulus is applied to a 
sensory afferent nerve.  Peripheral terminals have transducer channels, TPRV1-4, 
TRPM8, TRPA1 (1-2 transducer types per neuron), that allow cation entry to initiate 
generator and action potentials by way of specific sodium channels, Nav 1.6-1.9.  At the 
central terminal, Ca2+ influx by way of voltage-gated calcium channels (Cav) initiates 
neurotransmitter release, i.e., glutamate (modified from Woolf and Ma, 2007). 
 
Arrival of action potential at the central terminal causes the opening of voltage gated calcium ion 
channels (Diag. II). An influx of calcium ions occurs producing a transient rise in intracellular 
calcium (Gover et al., 2003) and depolarization-induced, calcium-facilitated neurotransmitter 
release (Chen et al., 1999; Woolf and Salter, 2000). Neurotransmitters are released by an 
exocytosis process using t- and v-soluble NSF (N-ethylmaleimide sensitive fusion proteins) 
attachment protein receptor (SNARE) complexes. For example, synaptobrevin (also called 
vesicular associated membrane protein 2 [VAMP 2]) is a v-SNARE protein in synaptic vesicles 
that is inhibited by SNARE-master proteins such as synaptophysin I (Gerst, 2002).  
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Synaptophysin I, therefore, is very important in regulating neurotransmitter release (Lynch et al., 
1994) and is used as a marker for synaptic vesicles (Masliah et al., 1990; Edelmann et al., 1995; 
Bacci et al., 2001; Sun et al., 2006; Gonzalez-Jamett et al., 2010; Wagget et al., 2010; Bamji et 
al., 2003). When intracellular calcium levels rise in a terminal, the synaptophysin/synaptobrevin 
complex dissociates (Reisinger et al., 2004) to allow synaptobrevin to interact with t-SNARES, 
e.g., syntaxin and SNAP 25, on the plasma membrane (Reisinger et al., 2004). The t- and v-
SNARE complex of synaptobrevin, syntaxin and SNAP 25 is a helix protein complex that is 
required for vesicle/plasma membrane fusion (Diag. III;(Reisinger et al., 2004). 
 
After dissociation from synaptobrevin and exocytosis, synaptophysin I binds to dynamin in a 
calcium dependent fashion for recovery of vesicular membrane from plasma membrane by 
endocytosis (Daly et al., 2000). During endocytosis, dynamin assembles to form rings at the base 
of membrane invaginations, GTP binds to dynamin, and hydrolysis of GTP causes a 
conformational change of the membrane for vesicle fission (Oh et al., 1998). Synaptophysin I 
thus has a pivotal role in both endocytosis and exocytosis of synaptic vesicles. 
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Neurotransmitter release at a nerve terminal 
 
Diagram III. Schematic showing the series of events that occur with arrival of action 
potential at a nerve terminal. Depolarization of the nerve terminals (action potential) 
occurs with voltage dependent opening of sodium (blue channel in diagram) and 
potassium (green channel in diagram) channels allowing influx of sodium ions and then 
efflux of potassium ions. Local depolarization causes voltage gated calcium channels to 
open (red channel in diagram) allowing influx of calcium ions and increase in 
intracellular calcium concentration. Intracellular calcium triggers the dissociation of the 
synaptophysin-synaptobrevin complex thus allowing synaptobrevin to associate with 
SNAP 25 and syntaxin to form functional SNARE complexes, followed by fusion and 
exocytosis of neurotransmitters, such as glutamate. After exocytosis, neurotransmitters, 
such as glutamate, bind to and open receptors on the postsynaptic neurons.  
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Synaptophysin I has a molecular homologue, synaptoporin (synaptophysin II), with almost 60% 
sequence homology. Both proteins have four transmembrane domains and two hydrophilic loops 
within the vesicle, i.e., intravesicular loops. Divergence occurs at their N- and C-terminals that 
are exposed to the cytoplasmic side.  Both synaptophysin I and synaptoporin are expressed in the 
central and peripheral nervous systems (CNS, PNS). Synaptophysin I is abundantly expressed in 
the CNS whereas synaptoporin expression is restricted (Masliah et al., 1990, Sun et al., 2006). In 
the PNS, both synaptophysin and synaptoporin are expressed in nociceptive dorsal root ganglion 
(DRG) neurons, i.e., small diameter DRG neurons, and their afferent terminals in the dorsal 
spinal cord (Sun et al., 2006). Some of these DRG neurons coexpress calcitonin gene-related 
peptide (CGRP), a nociceptive peptide transmitter. Abundant synaptoporin containing nerve 
fibers occur in the laminae I-II of dorsal horn of spinal segments L4-5 while abundant 
synaptophysin I containing nerve fibers occur in laminae III–IV and ventral lamina II. 
 
1.2 Glutamate in nociceptors 
The glutamate-glutamine cycle. Glutamate is the major excitatory neurotransmitter in the 
vertebrate nervous system and is released from nociceptors at both the peripheral and central 
nerve terminals. Glutamate metabolism in the PNS occurs via a glutamate-glutamine cycle (Diag. 
III) where glutamate enters the satellite and Schwann glial cells and is converted to glutamine by 
glutamine synthetase (Curie and Kelly, 1981; Miller et al., 2002; Miller et al., 2011a). In DRG, 
neurons take up glutamine and glutaminase converts glutamine to glutamate (Miller et al., 1992; 
(Hassel et al., 2003).  Glutamate also is produced by aspartate aminotransferase by transamination 
of aspartate to 2-oxoglutarate, yielding glutamate and oxaloacetate (Miller et al., 2002; Miller et 
al., 2011a). 
 
Following synthesis, glutamate is packaged into synaptic vesicles by vesicular glutamate 
transporters (Juge et al., 2006, Brumovsky et al., 2007). Vesicular glutamate transporter 1 or 2 
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(VGLUT1, 2) upload glutamate into synaptic vesicles for the transport and release of glutamate  
(Aihara et al., 2000; Juge et al., 2006; Moechars et al., 2006; Brumovsky et al., 2007; Miller et 
al., 2011a). The VGLUTs actively transport glutamate into the vesicles in exchange for hydrogen 
ions (Bellochio et al., 2000; Juge et al., 2006; Miller et al., 2011a). The electrochemical gradient 
for glutamate transport is created by hydrolysis of ATP (Bellochio et al., 2000; Juge et al., 2006). 
This transport is further enhanced in the presence of chloride ions (Bellochio et al., 2000; Juge et 
al., 2006; Miller et al., 2011a). Thus, vesicular glutamate transporters are considered markers of 
glutamatergic neurons (Brumovsky et al., 2007; Miller et al., 2011a).  
 
Both VGLUT 1 and VGLUT 2 are expressed by neurons in the DRG (Brumovsky et al., 2007). 
VGLUT 1 is localized in medium to large sized neurons that mediate proprioception and 
discriminative touch. VGLUT 2 is localized in small to medium sized nociceptive neurons that 
contain neuropeptides such as calcitonin gene-related peptide (CGRP) or bind lectins, such as 
isolectin B4 (IB4; (Brumovsky et al., 2007; Miller et al., 2011a). In the rat skin, VGLUT 2 
immunoreactivity in the dermal and intraepidermal plexus is of greater intensity than that DRG 
neuronal cell bodies (Brumovsky et al., 2007). In the spinal cord, VGLUT2 has a dense and 
homogenous distribution in the grey matter except in the medial aspect of laminae III–VI where 
VGLUT1has an intense distribution (Brumovsky et al., 2007). 
 
  
  
 
Diagram IV. Schematic of the glutamate
Schwann cell, glutamine synthetase (GS) converts glutamate
which is transported by the sodium coupled neutral amino acid transporters
the DRG neuron. Glutaminase (GLS) converts glutamine into glutamate and VGLUT 1
or 2 packages synthesized glutamate into synaptic vesicles. When glutamate is released, it 
is taken up back into the satellite 
glutamate-aspartate transporter
Miller et al., 2011a). 
 
Upon release from a neuronal terminal, glutamate can bind to excitatory amino acid 
(EAARs), i.e., glutamate receptors. 
metabotropic EAARs, and e
Lin and Kinnamon, 1999). The ionotropic
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Types of Ionotropic EAARs and their Subunits
Diagram V. Schematic of the different types of ionotropic
receptors, i.e, glutamate receptors
of ionotropic glutamate receptors
AMPA (2-amino-3-(5-m
NMDA has NR1 and NR2A
and GluR 5-7 and KA1
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the requirement of NR1 subunit as a part of all NMDA receptor channels. A common NMDA 
receptor construct consists of two NR1 and two NR2 subunits (Diag. VI; Monyer et al., 1994) 
The NMDA receptor also expresses glycine binding site, a site needed for channel function 
(Oliver et al., 1990; Monyer et al., 1994). When glycine binds to this site, it functions as a co-
agonist and positive modulator of the NMDA receptor. This ion channel also is blocked by 
extracellular magnesium ions and removal of magnesium block is voltage dependent (Mayer and 
Westbrook, 1987; Monyer et al., 1994).   
 
The AMPA receptor subunits exist as tetrameric homomers or heteromers. Unlike 
heteromers,homomers have not been observed to contribute significantly to the AMPA excitatory 
postsynaptic potential (EPSP; Lu et al., 2009). AMPA heteromers tend to prefer GluR2 dimers 
with a dimer either of GluR1, GluR3, or GluR4. Each AMPA subunit has a binding site for 
glutamate, i.e., four glutamate binding sites per AMPA receptor (Mayer and Armstrong, 2004; 
Greger et al., 2007). 
 
Both KA1 and KA2 subunits of the kainate receptor have been described as being obligatory 
subunits for the ionotropic kainate receptor function and are termed the high affinity subunits 
(Lucifora et al., 2006; Fernandes et al., 2009). Homomers of KA1 or KA2 are nonfunctional 
(Herb et al., 1992, Fernandes et al., 2009), but, when co-expressed with the GluR5-7 subunits, 
they form functional heteromeric receptors (Herb et al., 1992; Dingledine et al., 1999; Fernandes 
et al., 2009). 
 
1.3 Glutamatergic function of peripheral nociceptor terminals 
Glutamate release from peripheral terminals may occur following intense stimulation of the 
primary afferent nerves. Stimulated glutamate release occurs due to mechanical nerve injury 
(Belmonte et al., 1997; Du et al., 2001; Julius and Basbaum, 2001; Miller et al., 2011a), chemical 
  
 
activation (Belmonte et al., 1997
Peng et al., 2011; Miller et al., 2011a
2001). It has been proposed that glutamate release from nociceptor peripheral terminals may 
sensitize surrounding nerve fibers causing hyperalgesia
(Cairns et al., 2001; Du et al., 2001
painful stimuli (Diag. VII). 
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Along with phosphorylation of TRP and sodium channels (described earlier), sensitization also is 
due to interaction with EAARs on peripheral afferent terminals. Glutamate interacts with EAARs 
on afferent terminals and directly activates sensory nerve endings (Du et al., 2001; Du et al., 
2003; Du and Carlton, 2006; Miller et al., 2011a). Anatomical studies have localized EAARs on 
unmyelinated axons in the skin (Carlton et al., 1995; Coggeshall et al., 1997; Coggeshall and 
Carlton, 1998; Du et al., 2003; Miller et al., 2011a). For example, the following EAAR subunits 
have been demonstrated on unmyelinated nerve fibers in rat hairy and glabrous skinwith electron 
microscopic immunohistochemistry (Carlton et al., 1995, Coggeshall and Carlton, 1998): NMDA 
NR1 (21-30% of unmyelinated nerves in rat sural plantar nerves), NR2B, GluR1 (8-17% in rat 
sural and plantar nerves), GluR2/3 and GluR5-7 (7-44% in rat sural and plantar nerves). Studies 
also have demonstrated that the glutamate released from nociceptor peripheral terminals 
participates in neurogenic inflammation (Du et al., 2001, Richardson and Vasko, 2002, Miller et 
al., 2011a; Hoffman and Miller, 2010). This indicates an interaction of glutamate with EAARs in 
peripheral tissues (Cairns et al., 2001, Du et al., 2001, Du et al., 2003, Du and Carlton, 2006, 
Miller et al., 2011a). As in spinal cord, glutamate is co-released along with SP and CGRP and 
these three neuroactive agents promote the production of other local inflammatory mediators such 
as prostaglandin and bradykinin (Belmonte et al., 1997; Marfurt et al., 2001; Richardson and 
Vasko, 2002; Miller et al., 2011a). Prostaglandin and bradykinin also interact with peripheral 
nerve terminals and the net effect is a reduction in activation threshold of the nociceptors (Du et 
al., 2001; Miller et al., 2011a).  
 
Evidence for peripheral glutamate release from nociceptors along with localization of EAARs on 
peripheral afferents may explain why exogenous glutamate or its agonists cause sensitization and 
pain in experimental animals and humans (Carlton et al., 1995; Coggeshall and Carlton, 1998; 
Cairns et al., 2001; Du et al., 2001; Du et al., 2003; Du and Carlton, 2006; Miller et al., 2011a). 
This also is consistent with studies that show up-regulation of glutamate receptors in primary 
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afferents during inflammation (Peng et al., 2011), such that the sensitized nociceptor has an 
augmented response on further exposure to glutamate. The phenotypic alterations in primary 
afferents during ongoing inflammation or nerve injury are thought to form the basis for 
maladaptive pain, i.e., spontaneous pain, hyperalgesia and allodynia (Diag. VII).    
 
Although it is clear that glutamate is released from peripheral afferent terminals (Miller et al., 
2011a), it is unknown what cellular synaptic proteins are involved in peripheral glutamate release. 
In the cornea, there is evidence that glutamate and other neurotransmitters are present (Marfurt et 
al., 2001; Muller et al., 2003; Langford et al., 2010; Miller et al., 2011b), however the glutamate 
release mechanism and its role in corneal nociception are not fully understood. Glutamate and 
excitatory amino acid transporters have been identified recently in human superficial corneal 
epithelial cells and stroma, but no reference has been made to corneal peripheral afferents 
(Langford et al., 2010). As with skin peripheral afferents, we hypothesize that glutamate in 
corneal peripheral afferents may play an important role in sensitization of corneal afferent nerves 
via EAARs. 
 
1.4 Sensory innervation of the cornea 
The cornea receives its sensory innervation from the ophthalmic division of the trigeminal 
ganglion (Muller et al., 1997, Marfurt et al., 2001). The ophthalmic branch divides to form the 
long and short ciliary nerves that pierce the sclera at the posterior pole of the eyeball and around 
the optic nerve (Marfurt et al., 2001). The cornea receives its sympathetic innervations from the 
superior cervical ganglion and parasympathetic innervations from the ciliary and pterygopalatine 
ganglia (Belmonte et al., 1997, Marfurt et al., 2001). Some corneal sensory nerve fibers are 
nonmyelinated while others are myelinated (Belmonte et al., 1997), but lose their myelin on entry 
into the cornea in order to maintain corneal transparency (Muller et al., 2003).  
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Sensory Innervation of the Cornea 
 
Diagram VIII. Schematic of corneal innervation. The ophthalmic division of the 
trigeminal ganglion branches to form the long and short ciliary nerves. These travel 
anteriorly in the sclera to enter the corneal stroma in bundles and in a radial fashion.  The 
figure above shows a large stromal bundle that branches extensively to innervate the 
other parts of the cornea (Chan-Ling, 1989). These branches anastomose to form the 
subepithelial plexus (SEP). Branching lease fibers from the SEP enter into the epithelium 
where they terminate as free nerve endings (Beckers et al., 1993). SEP -subepithelial 
plexus, BL -basal epithelial leashes, IT - intraepithelial terminals. (Diagram from Chan-
Ling, 1989) 
 
Within the cornea, the stromal nerve bundles divide to form plexuses that supply the anterior 
stroma and corneal epithelium (Diag. VIII; Marfurt et al., 2001). A subepithelial nerve plexus is 
formed and axons from it innervate the superficial corneal epithelial cells (Belmonte et al., 1997). 
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Studies have demonstrated the presence of corneal epithelial leash formations from the 
subepithelial plexus (Belmonte et al., 1997, Marfurt et al., 2001, Muller et al., 2003). A leash is 
composed of 2 to 6 axons occurring in association with the subepithelial plexus (Marfurt et al., 
2001). The leashes were described as beaded, running tangential to the corneal surface and are 
parallel to one another with a common orientation (Marfurt et al., 2001). These terminate within 
the epithelium as free nerve endings (Diag. VIII; Beckers et al., 1993). 
 
There are 2 types of corneal afferent neurons, the thin myelinated A delta nerve fibers and the 
unmyelinated C nerve fibers (Belmonte, 1997). The A delta fibers lose their myelin on entry into  
The cornea (Muller et al., 2003) such that all corneal nerves are devoid of myelin sheath. As in 
the skin, muscle, and joints, noxious sensing neurons in the cornea are called nociceptors. There 
is evidence that different types of corneal nociceptors exist (Belmonte et al., 2003): 
mechanonociceptors, polymodalnociceptors, cold nociceptors and silent nociceptors (Belmonte et 
al., 2003). Electrophysiological studies indicate that mechanonociceptors discharge in response to 
damaging mechanical stimuli, whereas polymodalnociceptors discharge in response to a number 
of stimuli such as carbon dioxide, ATP, endogenous chemicals, low threshold mechanical stimuli 
and temperatures above 39°C and below 29°C. Cold nociceptors discharge when the temperature 
of the corneal surface falls below normal temperature of 33°C (Belmonte et al., 2003). Silent 
nociceptors do not discharge under normal circumstances, but become responsive when they are 
sensitized (Belmonte et al., 2003). As with other peripheral nociceptive afferents, these sensory 
neurons express proteins known as transducers to respond to noxious stimuli. For example, 
TRPV1, the noxious heat transducer, and TRPM8, the noxious cold transducer, have been 
identified and described in the cornea (Madrid et al., 2006; Murata and Masuko, 2006; 
Mergler et al., 2010 ). 
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1.5 The Role of Glutamate in the Cornea 
Our laboratory has shown that primary sensory corneal afferent nerve fibers contain glutamate, 
glutaminase, and aspartate aminotransferase (Miller et al., 2011b). Furthermore, another study has 
localized glutamate in the superficial corneal epithelial cells (Langford et al., 2010). Even though 
there is evidence that glutamate is released into the human cornea (Langford et al., 2010), its 
mechanism of release, the presence of glutamate receptors in the cornea, and the effect of 
stimulation of these receptors on behavior is largely unknown. This current dissertation project 
will identify the presence of molecular machinery for glutamate release in the cornea as a way of 
demonstrating the potential for vesicular release of glutamate and other neurotransmitters into the 
cornea. It will focus on immunohistochemistry for synaptophysin, a presynaptic marker for 
synaptic vesicles, and VGLUT, a marker of glutamatergic synaptic vesicles in corneal sensory 
afferents. Immunohistochemistry will be verified with a Western blotting study. A retrograde 
tracing study from the cornea to the trigeminal ganglion (TG) coupled with 
immunohistochemistry also will be performed to demonstrate that corneal TG neuronal cell 
bodies produce synaptophysin I and VGLUT2. In order to determine if glutamate can interact 
with afferents or resident tissue cells, a second study will localize various subunits of NMDA, 
AMPA, and kainate EAARs in the cornea by immunohistochemistry, specifically the NMDA 
NRl, the AMPA GluR1 and GluR2/3, and the kainate KA2 and GluR5 subunits. A third study 
will determine the relative contributions of corneal glutamate receptors on the behavioral 
response to glutamate and its ionotropic receptor agonists, NMDA, AMPA and kainate. The 
effect of ionotropic glutamate receptor antagonists on agonist induced corneal nociception will be 
evaluated using the following antagonists: D-AP5 (D-(-)-2-amino-5-phosphonopentanoic acid 
[NMDA antagonist]), NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulfonamide disodium salt [AMPA antagonist]) and CNQX (6-cyano-7-nitroquinoxaline-2,3-
dione disodium salt [AMPA/kainate antagonist]).  
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1.6 Hypotheses 
1. Glutamate release into the cornea occurs via synaptic vesicles. 
2. Ionotropic excitatory amino acid (glutamate) receptors are present in the rat cornea. 
3. Corneal excitatory amino acid receptors play a role in corneal nociception and EAAR 
antagonists diminish agonist-induced corneal nociception. 
 
1.7 Aims 
1. Determine if molecular machinery for vesicular glutamate release is present in rat cornea 
with immunohistochemistry. Verify immunohistochemistry with Western blotting.  
Detect molecular machinery for vesicular glutamate release in corneal trigeminal 
ganglion neurons. (Chapter 2) 
2. Localize excitatory amino acid receptor subunits in the rat cornea with 
immunohistochemistry. Detect excitatory amino acid receptor subunits in corneal 
trigeminal ganglion neurons. (Chapter 3) 
3. Evaluate the effect of glutamate and ionotropic excitatory amino acid receptor agonists 
(NMDA, AMPA and kainate) on behavioral responses in the intact cornea. Determine if 
antagonism of excitatory amino acid receptors reduces agonist-induced behavioral 
responses. (Chapter 4) 
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CHAPTER 2 
 
 
SYNAPTIC PROTEINS AND VESICULAR GLUTAMATE TRANSPORTERS IN RAT 
CORNEA 
Abstract 
Aim: To determine if molecular machinery for vesicular glutamate release is present in the rat 
cornea. Primary afferents in the cornea contain glutamate, substance P, and calcitonin gene-
related peptide.  It is unclear if these neurotransmitters are released by vesicular mechanisms as in 
the central nervous system.  The aim of this study, therefore, was to describe, in the rat cornea, 
the localization of proteins involved in synaptic vesicle neurotransmitter release: synaptophysin I 
and II; vesicular glutamate transporter 1 and 2 (VGLUT1, 2); synaptosomal-associated protein 25 
(SNAP-25). 
 
Method: Corneas from Sprague Dawley rats were processed for immunohistochemistry. Whole 
mounts and tissue sections were incubated in primary antisera against VGLUT2 and 
synaptophysin I. Also, retrograde tracing from the cornea with Fluorogold was used to identify 
corneal trigeminal neurons with synaptophysin I and VGLUT2. In addition, corneas were 
evaluated with Western blots to detect synaptophysin I and VGLUT2.  
 
Results: VGLUT2- and synaptophysin I-immunoreactive afferent nerves were found in the 
corneal epithelium, stroma and endothelium. These fibers were varicose and exhibited an 
extensive branching pattern. The presence of VGLUT2 and synaptophysin I in the cornea was 
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verified further on Western blots. There was also VGLUT2 and synaptophysin I 
immunoreactivity on corneal trigeminal ganglion neurons.  
 
Conclusion: These data indicate a mechanism for release of glutamate into the cornea. This 
mechanism may provide a novel outlook on the pharmacological means of regulating corneal 
physiology during inflammation and nerve injury. 
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2.1 INTRODUCTION 
Glutamate is the excitatory neurotransmitter used by primary sensory neurons located in 
trigeminal and dorsal root ganglia (Miller et al., 2011a).  In addition to use as an excitatory 
neurotransmitter in the central nervous system, nociceptive primary sensory neurons to the skin 
and muscle peripherally release glutamate along with substance P (SP) and calcitonin gene-
related peptide (CGRP) as part of the neurogenic inflammatory response (Du et al., 2001, 
Richardson and Vasko, 2002, Du et al., 2003, Miller et al., 2011a). Glutamate’s peripheral 
transport occurs in synaptic vesicles (Juge et al., 2006) containing vesicular glutamate 
transporters 1 or 2 (VGLUT1 or VGLUT2; Aihara et al., 2000, Bellochio et al., 2000, Moechars 
et al., 2006, Brumovsky et al., 2007, Miller et al., 2011a). These transporters are responsible for 
loading synaptic vesicles with glutamate. There also is evidence that glutamate is released into 
the cornea (Langford et al., 2010; Miller et al., 2011b) along with other neurotransmitters such as 
substance P (SP) and calcitonin gene-related peptide(Sasaoka et al., 1984; Beckers et al., 1992; 
Beckers et al., 1993; Marfurt et al., 2001). A mechanism of release for neurotransmitters such as 
glutamate from corneal afferents has not been studied.  
 
Synaptophysin (I or II) is an integral protein of the synaptic vesicle (Sun et al., 2006) where it 
plays a role in regulating the amount of neurotransmitter released during exocytosis (Gonzalez-
Jamett et al., 2010). Synaptophysin binds synaptobrevin, a vesicle-soluble NSF attachment 
protein receptor (v-SNARE) protein, to prevent synaptic vesicle docking (Gertz et al., 1999). 
Upon depolarization, intracellular calcium levels rise in a nerve terminal causing synaptophysin 
and synaptobrevin to dissociate. Synaptobrevin interacts with target-SNAREs (t-SNARE), such 
as synaptosomal-associated protein 25 (SNAP-25), for vesicular exocytosis. 
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Studies show that synaptophysin I and II are localized to neurons in the dorsal root ganglion (Sun 
et al., 2006) and trigeminal ganglion (Tarsa and Balkowiec, 2009). The peripheral afferents of 
these sensory neurons are distributed to tissues such as the skin and cornea. If corneal afferents 
release glutamate from their peripheral terminals, then proteins responsible for release should be 
localized to the cornea. This current study, therefore, focused on the description of 
immunohistochemical labeling of synaptophysin I and II, SNAP 25, and VGLUT 1 and 2 in the 
cornea. The presence of these proteins synaptophysin I and VGLUT2 was confirmed with 
Western blotting. Retrograde tracing from the cornea was used to verify the presence of 
synaptophysin I and VGLUT2 in TG.   
 
2.2 METHODOLOGY 
2.2.1 Immunohistochemistry 
2.2.1.1 Tissue preparation 
Adult Sprague Dawley rats (n=12) were euthanized with Avertin (i.p.) followed by xylazine 
(i.p.).  The thorax was opened and animals were perfused transcardially via the ascending aorta 
with 100ml of calcium free Tyrrode’s buffer (23°C) followed with 300ml of fixative: 0.8% picric 
acid, 0.2% paraformaldehyde and 0.1 M phosphate buffer (23°C), pH 7.4 (Hoffman et al., 2010). 
The bulbus oculi was enucleated and cornea excised. The tissues were incubated for 2 to 3 hours 
in fixative and transferred to phosphate buffered saline (PBS) in 10% sucrose overnight.  Corneas 
were processed for immunohistochemistry as whole mounts or sagittal tissue sections.  For tissue 
sections, the corneas were frozen in M-1embedding matrix (Lipshaw) and 10µm sagittal sections 
were cut in the cryostat at -21˚C.  Tissue sections were thaw-mounted onto gelatin coated glass 
slides.  
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The whole mounts and tissue sections were rinsed three times in PBS.  Subsequently, they were 
processed for immunohistochemistry using rabbit anti-VGLUT 2 (Sigma,HY19, 1/2000), rabbit 
anti-SNAP 25 (ABD Serotec, 1/20000), rabbit anti-synaptophysin I (Chemicon, 1/5000), and 
rabbit anti-synaptophysin II (Chemicon, 1/5000).  Tissues were incubated on a shaker at 4°C for 
120hr.  Tissues were rinsed three times with PBS, 10 minutes each, and incubated in biotinylated 
goat anti-rabbit IgG (Jackson, 1/8000 dilution). The tissues were rinsed three times in PBS, 10 
minutes each, and incubated in streptavidin-HRP (Invitrogen, 1/1000 dilution) for 60 minutes. 
The tissues were rinsed three times in PBS, 10 minutes each, and were incubated for 10 minutes 
in 200µl of tyramide solution (1/400 dilution) and amplification buffer with 0.3% hydrogen 
peroxide. Whole mounts were placed on glass slides.  Coverslips were apposed using Prolong 
Gold mounting medium (Vector) and incubated overnight at room temperature. Images were 
obtained using a Spot camera (Diagnostic Instruments) attached to an Olympus BX51 
epifluorescence microscope.  
 
2.2.1.2 Removal of corneal epithelium with thermolysin 
In order to examine the stromal corneal afferents, corneas were treated with thermolysin (Endo et 
al., 2004) in the following manner.  Adult Sprague Dawleyrats (n = 3)were asphyxiated with 
carbon dioxide. The bulbus oculi was enucleated and corneas excised.  Corneas immediately were 
incubated in a solution containing 5ml of thermolysin (1:4 dilution in PBS; Sigma) and 5µl of 1M 
calcium chloride at 4°C for 30 minutes.  To stop the enzymatic reaction, the tissues were 
incubated in 1ml of 0.5M EDTA and 100ml of DMEM (Dubelcco’s modification of Eagles 
medium; Invitrogen) for another 30 minutes. The epithelium was separated from the stroma by 
gentle scraping with a scalpel blade. The stroma was post fixed in picric acid fixative (0.8% picric 
acid, 0.2% paraformaldehyde and 0.1 M phosphate buffer at pH of 7.4) and subsequently 
processed for whole mount immunohistochemistry as described above.  
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2.2.2 Retrograde tracing:  
Adult Sprague Dawley rats (n = 8) were anaesthetized with Isofluorane, the eyelids were parted 
and 10-20µl of 5% fluorogold was injected with a Hamilton syringe into the cornea using a 
dissecting microscope. Spills from the injection site immediately were wiped off with cotton 
tipped applicator and subsequently irrigated with distilled water.  Animals were allowed to 
recover from anesthesia before returning them to their cages. After 5 days, the animals were 
euthanized with Avertin (i.p.) followed by xylazine (i.p.) and transcardially perfused with fixative 
as described earlier.  Ipsilateral trigeminal ganglia were removed and cryostat sections at 10-
20µm were processed for synaptophysin I and VGLUT2 immunoreactivity as described above. 
2.2.3 Western blot 
Fresh cornea and trigeminal ganglia (positive control) were obtained from adult Sprague Dawley 
rats (n =3)and homogenized using lysis buffer (8M urea, 50mM TrisHCl, 1mM dithiothreitol and 
1mM EDTA,pH 7.4, 4°C) and phosphatase inhibitor cocktail I and II and protease inhibitor 
(Sigma). Homogenates were centrifuged (70,000 rpm, 20 minutes) and the protein concentration 
of the supernatant was measured (BCA Protein Assay Kit, Pierce, Rockford, IL) to normalize the 
samples.  Rabbit anti-VGLUT2 antibody (Sigma, HY19) and rabbit anti-synaptophysin I 
(Chemicon) were conjugated M-280 Dynabeads (Schechter et al., 2005); Miller et al., 2012).  
Equal amounts of total protein (75mg/ml) were exposed to rabbit anti-synaptophysin I antibody-
beads or rabbit anti-VGLUT2 antibody-beads (16 hr, 4°C) for protein purification (Schechter et 
al., 1998).  Samples were exposed to a magnet to collect the bead-antibody-protein complex.  The 
purified VGLUT-2 or synaptophysin I was eluted from the beads using Lammelli buffer (10mM 
Tris Base, 1mM EDTA, and 2.5% SDS%, 3β-mercaptoethanol and 0.01% bromophenol blue) and 
heating the samples at 100°C for five minutes.  
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Gel electrophoresis was performed using a 12.5% polyacrylamide gel (GE Healthcare; Phast-
System, Promega) along with molecular weight standards (Novagen; Schechter et al., 2005). 
Separated proteins were transferred to a nitrocellulose membrane using the PhastSystem in a 
buffer of 25 mMTris, 192 mM glycine and 20% methanol, pH 8.0 at 25mA for 20 minutes. 
Immunoblotting was performed using the Protoblot II AP System (Promega).  Membranes were 
dried at 37°C, rinsed in 20 mMTris-HCL, 150 mMNaCl and 0.05% Tween 20, pH 7.5 (TBST), 
washed in 1% bovine serum albumin (BSA) in TBST and incubated in rabbit anti-synaptophysin I 
(1:1000) or rabbit anti-VGLUT2 (1:2000) antisera for 1 hour at room temperature.  Membranes 
were washed in TBST followed by incubation in alkaline phosphatase conjugated goat anti-rabbit 
antibody for 30 minutes and washed twice in TBST and TBS.  Membranes were incubated in 
Western Blue stabilized substrate for alkaline phosphatase (Promega; 5-bromo-4-chloro-3-
indolyl-phosphate, nitro blue tetrazolium) for immunoreactive detection. 
 
2.3 RESULTS  
2.3.1 Immunohistochemistry  
Immunoreactivity was not observed for synaptophysin II or VGLUT 1 in corneal whole mounts 
or tissue sections.  Corneal afferent nerves were immunoreactive (IR) for VGLUT 2. The whole 
mounts show intense VGLUT2 immunoreactivity in the epithelium such that it was difficult to 
delineate the layers of the cornea. For this reason, the corneal epithelium was removed with 
thermolysin. Following the removal of the corneal epithelium, numerous nerve fibers were 
visualized traveling through the stroma (Fig. 2.1.1). These nerve bundles displayed extensive 
branching pattern. On the sagittal sections (Fig.2.1.2), VGLUT2-IR nerve fibers were found in 
the epithelium (Fig 2.1.2 and 2.1.3), stroma and endothelium (Fig. 2.1.2). In the epithelium and 
endothelium, VGLUT 2-IR afferents fibers exhibit varicosities along their trajectories and were 
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seen as scattered punctae throughout the stroma. Within the endothelium (Fig2.1.2), varicose IR 
fibers travel along most of the entire length of the endothelium. Retrograde tracing indicated that 
corneal trigeminal ganglion neurons were labeled and that small to medium diameter neurons had 
VGLUT 2 immunoreactivity (Fig. 2.2). 
 
Synaptophysin I-IR varicose nerve fibers were localized in corneal whole mounts and tissue 
sections (Fig. 2.3). There were numerous synaptophysin I-IR beaded nerve fibers in the 
epithelium, endothelium and stroma (Fig. 2.3.2 and 2.3.3). Some synaptophysin I-IR corneal 
epithelial nerves fibers initially travel parallel to the corneal surface, but turn abruptly, almost at 
right angles, to terminate within the superficial corneal epithelium. Within the stroma, varicose 
synaptophysin I-IR nerve bundles were observed. In the endothelium, synaptophysin I-IR corneal 
nerve fibers could be seen along the entire length of the endothelium. Retrograde tracing 
demonstrated labeled corneal trigeminal ganglion neurons with synaptophysin I immunoreactivity 
(Fig. 2.4). 
In corneal whole mounts, there were numerous varicose SNAP 25-IR corneal nerve fibers (Fig. 
2.5). The SNAP 35-IR nerve fibers in the stroma had extensive branching before entering the 
subepithelial plexus. 
 
2.3.2 Western blots  
Western blotting was used to verify the presence of VGLUT2 and synaptophysin I in intact rat 
cornea. A single VGLUT 2-IR band from the cornea occurred at 65 kiloDaltons (kDa;Fig. 2.6).  
A single synaptophysin I-IR band at 38 kDa was obtained from the rat cornea (Fig. 2.7).  
Trigeminal ganglia were used as positive controls and showed comparable bands at 65Kd for 
VGLUT2 and 38Kd for synaptophysin I. 
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Figure 2.1.VGLUT2 Immunohistochemistry in the rat cornea.In figure2.1.1 (corneal whole 
mount), the epithelium was been removed to reveal the underlying VGLUT2-IR stromal nerve 
bundles with their extensive pattern of branching (white arrows). Sagittal section (10µm) of the 
rat cornea (Fig 2.1.2 and 2.1.3). The white arrows show VGLUT2-IR nerve fibers in the corneal 
epithelium, stroma and endothelium (Fig 2.1.2). Intensely labeled VGLUT2-IR nerves can be 
seen within the corneal epithelium (Fig.2.1.3). 
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Figure 2.2. Retrograde tracing study
Trigeminal ganglion neurons were retrogradely labeled with fluorogold (Fig 2
Neuronal cell bodies in the trigeminal ganglion were IR for VGLUT2 (Fig 2
arrowheads). Small-medium diameter fluorogold neurons contained VGLUT 2 immu
(Fig 2.2.3, arrows). 
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Figure 2.3. Synaptophysin I immunohistochemistry in the rat cornea.Corneal whole mount 
showing synaptophysin I-IR corneal afferents (Fig 2.3.1) as indicated by the white arrows. 
Sagittal section (10µm) of the rat cornea shows IR afferents in the epithelium, stroma and 
endothelium (Fig 2.3.2). In figure 2.3.3, the white arrows show varicose synaptophysin I IR 
afferents within the corneal epithelium.   
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Figure2.4. Retrograde tracing study
ganglion. Trigeminal ganglion neurons were retrogradely labeled with fluorogold (Fig 
arrows). Neuronal cell bodies in the trigeminal ganglion were IR for synaptophysin (Fig 
arrows and arrowheads).  Fluorogold la
immunoreactivity (Fig 2.1.3
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Figure2.5. SNAP25 immunoreactivity
arrows point to SNAP25-IR
numerous and branched within the stroma of the cornea
 
Figure 2.6. Western blot detection of VG
2-IR band was detected from the trigeminal ganglia and cornea. Numbers on the right indicate 
positions of molecular weight markers in kiloDaltons (kDa).
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Figure2.7. Western blot detection of 
synaptophysin I-IR band was detected from the trigeminal ganglia and cornea. Numbers on the 
right indicate positions of molecular weight markers in kiloDaltons (kDa).
 
2.4 DISCUSSION 
In skin and joint, glutamate
terminals to sensitize surrounding nerve terminals and cells and initiate neurogenic inflammatory 
cascades (Woolf and Ma, 207; Miller et al., 2011a
require depolarization of primary afferent terminals with high threshold stimulation (Miller et al., 
2011a).  In the cornea, there is evidence that glutamate
nerve fibers (Beckers et al., 1992, Beckers et al., 1993, Marfurt et al., 
but a mechanism for peripheral release has not been explored.  
synaptic vesicle proteins, synaptophysin I and VGLUT2
primary afferent immunoreactive
VGLUT 2 was verified with Western blotting. Their origin from A
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synaptophysin I in the rat cornea. At ~38 kDa, a single 
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neuronal cell bodies (small-medium diameter; Hoffman et al., 2010) was determined by 
retrograde tracing coupled with immunohistochemistry for synaptophysin I and VGLUT 2. 
 
VGLUTs are required for synaptic vesicle loading and storage of glutamate for neurotransmission 
(Bellochio et al., 2000; Juge et al., 2006; Moechars et al., 2006; Brumovsky et al., 2007; Miller et 
al., 2011a). Primary sensory neurons in DRG and TG express VGLUT1 or 2 and mouse sciatic 
nerve axons and intraepidermal afferents contain VGLUT2 (Brumovsky et al., 2007).  Glutamate 
and other neurotransmitters are released from nerve terminals by an exocytotic process using 
complexes of t- and v-SNAREs. For example, the v-SNARE of synaptic vesicles, synaptobrevin, 
is inhibited tonically by synaptophysin via a calcium mediated process (Gerst, 1999).  Upon nerve 
terminal depolarization, elevated intracellular calcium levels cause the synaptophysin-
synaptobrevin complex to dissociate and synaptobrevin is able to interact with syntaxin and 
SNAP 25, t-SNARES, on the plasma membrane (Reisinger et al., 2004).  The synaptobrevin, 
syntaxin and SNAP 25 helix complex is required for vesicle/plasma membrane fusion (Reisinger 
et al., 2004). Our results demonstrated the presence of SNAP 25, VGLUT2 and synaptophysin I 
in rat corneal afferents.  One interpretation of these results would be that glutamate is released 
into the cornea by vesicular exocytosis, potentially from high threshold sensory stimuli (Miller et 
al., 2011a).  
 
Previous studies show that branches of the long and short ciliary nerves enter the corneal stroma 
in bundles and in a radial fashion (Chan-Ling, 1989; Muller et al., 1997; Marfurt et al., 2001). 
These stromal nerve bundles divide to pierce Bowman’s membrane and form the subepithelial 
plexus. Branches from this plexus, termed leash fibers, enter into the epithelium and they 
terminate as free nerve endings (Chan-Ling, 1989; Muller et al., 1997; Marfurt et al., 2001). This 
previously reported sensory innervation pattern of the cornea matches with localization of 
VGLUT2 and synaptophysin I in this study. Varicosities in nerve fibers located in the peripheral 
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and central nervous systems are potential sites of “en passage” neurotransmitter release 
(Burnstock, 2007; Fuxe et al., 2010). The presence of VGLUT2 and synaptophysin I in varicose 
stromal and leash fibers may indicate release in the stroma and epithelium. The presence of 
immunoreactive varicose stromal and leash fibers may indicate that they have the potential for 
glutamate release, as well as epithelial free nerve endings.   
  
In skin, joint, and muscle, glutamate causes sensitization of peripheral afferents and other cell 
types in both normal and inflamed tissues (Du et al., 2001; Miller et al., 2011a).  Intense stimuli 
trigger vesicular release of glutamate from primary afferent nerves into peripheral tissues, such as 
the skin (Brumovsky et al., 2007; Miller et al., 2011a). Glutamate, released from nerve terminals, 
interacts with excitatory amino acid receptors (EAARs) on surrounding afferent nerves to lower 
their activation threshold, thereby causing peripheral sensitization (Du et al., 2001; Miller et al., 
2011a).  It is not known, however, if glutamate has similar sensitizing effects in the cornea via 
EAAR’s.  The identification of SNAP25, synaptophysin I and VGLUT2 in corneal peripheral 
afferents provides a foundation for determining the mechanism for peripheral glutamate release in 
the cornea.  Understanding the peripheral release of glutamate in the cornea may provide insight 
into corneal physiology during inflammation and tissue damage. 
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CHAPTER 3 
 
IMMUNOLOCALIZATION OF IONOTROPIC GLUTAMATE RECEPTORS 
 IN THE RAT CORNEA 
Abstract 
Aim: Immunohistochemical localization of select ionotropic excitatory amino acid receptor 
(EAAR; glutamate) subunits in intact rat cornea.   
 
Methods: Corneas from adult Sprague Dawley rats were fixed with paraformaldehyde/picric acid 
and processed for immunohistochemistry. Whole mounts and saggital tissue sections were 
incubated in primary antisera against EAAR subunits: 1. NMDA receptor subunit NR1 and 
phosphorylated NR1 (pNR1); 2.AMPA receptor subunits GluR1 and GluR2/3, 3. Kainate 
receptor subunits KA2. In addition, retrograde tracing from the cornea with Fluorogold was used 
to identify corneal trigeminal neurons with NR1, KA2, and GluR5 immunoreactivity. 
 
Results: Rat corneas were immunoreactive for NR1, pNR1, GluR1, GluR2/3, and KA2 subunits. 
Immunoreactivity for pNR1 occurred on the membrane of corneal epithelial cells and as scattered 
punctae within the epithelial cell nucleus. In addition, corneal epithelial nerve fibers were 
immunoreactive for the NR1 receptor subunit. Corneal epithelial cells were immunoreactive for 
GluR1, as well as GluR1 immunoreactive nerve fibers within the subepithelial plexus. Intense 
GluR2/3 immunoreactive granules were localized in the cytoplasm of corneal epithelial cells, as 
well as perinuclear clustering of immmunoreactive punctae. Epithelial cells were immunoreactive 
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for KA2 receptor subunit with scattered cytoplasmic punctae. Retrograde tracing from the cornea 
localized NR1, KA2, and GluR5 immunoreactivity in trigeminal neurons. 
 
Conclusion: These results indicate that ionotropic EAARs are localized to both rat cornea 
epithelial cells and corneal primary afferents. Glutamate released from corneal epithelial cells 
and/or afferents could produce sensitization of the cornea via NMDA, AMPA and kainate 
EAARs. 
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3.1 INTRODUCTION 
Glutamate is an excitatory neurotransmitter in central and peripheral axons of trigeminal and 
dorsal root ganglion neurons (TG, DRG; Miller et al, 2011a). Trafficking and release of 
glutamate in these sensory neurons occurs via vesicular glutamate transporter 1 or 2 (VGLUT1, 
2; Aihara et al., 2000, Bellochio et al., 2000, Moechars et al., 2006, Brumovsky et al., 2007, 
Miller et al., 2011a; Chapter 2 - Ibitokun, 2012).  Glutamate is released peripherally from primary 
afferent nerve fibers in skin, muscle and joint as part of the neurogenic inflammatory response 
where it exerts a sensitizing effect on surrounding afferents and resident and migrating 
inflammatory cells (Cairns et al., 2001, Du and Carlton, 2006, Miller et al., 2011a). This 
sensitizing effect occurs via ionotropic and metabotropic excitatory amino acid (glutamate) 
receptors (EAARs; (Du et al., 2001; Du et al., 2003; Du and Carlton, 2006; Peng et al., 2011; 
Miller et al., 2011a).  It is not known, however, whether EAARs are located in the cornea or if 
glutamate has a similar effect in the cornea as in other peripheral tissues. 
 
In the cornea, glutamate is present in human superficial epithelial cells and stroma (Langford et 
al., 2010) and rat corneal afferents (Miller et al., 2011b). Rat corneal afferents have VGLUT 2 for 
glutamate transport and storage (Chapter 2 - Ibitokun, 2012) and the release of glutamate from 
corneal afferents appears to occur via vesicular exocytosis using synaptophysin I and SNAP 25 
(synaptosomalassociated protein 25) (Chapter 2 - Ibitokun, 2012). If glutamate is released from 
afferents into the cornea, then sensitization of corneal afferents and cells may occur by interaction 
with iontotropic and/or metabotropic EAARs similar to what has been described in the rodent 
skin, joint, and muscle (Cairns et al., 2001; Du et al., 2001; Du et al., 2003; Du and Carlton, 2006; 
Brumovsky et al., 2007; Miller et al., 2011a).  The current study, therefore, will focus on 
localization of iontropic EAARs in the rat cornea.   
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Ionotropic glutamate receptors are classified into three types based on selective agonists: N-
methyl-D-aspartate (NMDA); 2-amino-3-(5-methyl-3-oxo-1, 2- oxazol-4-yl) propionate 
(AMPA); kainate (Wo and Oswald, 1995, Chen et al., 1996, Lu et al., 2009). These ionotropic 
receptors are comprised of subunits: NMDA - NR1, NR 2A-2D subunits; AMPA -GluR 1-4 
subunits; Kainate- KA1-2, GluR5-7 subunits (Wo and Oswald, 1995; Chen et al., 1996; Lu et al., 
2009). Previous immunohistochemical studies have localized EAARs on unmyelinated axons in 
the rat skin. For example, EAAR subunits (NR1, NR2B, GluR1, GluR2/3, GluR5-7) have been 
demonstrated on unmyelinated nerve fibers in rat hairy and glabrous skinwith electron 
microscopy (Carlton et al., 1995, Coggeshall et al., 1997, Coggeshall and Carlton, 1998, Du et al., 
2003, Du and Carlton, 2006). The NMDA NR1 subunit also has been localized to human and rat 
skin keratinocytes (Fischer et al., 2004a; Fischer et al., 2004b), Miller and Schechter  – 
unpublished observations). To further understand the potential role of glutamate in the cornea, 
this study aims at determining EAAR expression and localization in the rat cornea by 
immunohistochemistry and with retrograde tracing from the cornea to the TG coupled with 
EAAR immunohistochemistry.  
 
3.2 METHODOLOGY 
3.2.1 Immunohistochemistry. 
Adult Sprague Dawleyrats (n = 12)were euthanized with Avertin (i.p.) followed by xylazine 
(i.p.). The thorax was opened and animals were perfused transcardially via the ascending aorta 
with 100ml of calcium free Tyrrode’s buffer (23°C) followed with 300ml of fixative: 0.8% picric 
acid, 0.2% paraformaldehyde and 0.1 M phosphate buffer (23°C), pH 7.4 (Hoffman et al., 2010).  
The globe was enucleated and cornea excised. The tissues were incubated for 2 to 3 hours in 
fixative and transferred to phosphate buffered saline (PBS) in 10% sucrose overnight. Corneas 
were processed for immunohistochemistry as whole mounts or sagittal tissue sections.  For tissue 
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sections, the corneas were frozen in M-1 embedding matrix (Lipshaw) and 10µm sagittal sections 
were cut in the cryostat at -21˚C.  Tissue sections were thaw-mounted onto gelatin coated glass 
slides. 
 
The whole mounts and tissue sections were rinsed three times, 10 minutes each in PBS.  
Subsequently, they were processed for immunohistochemistry using the following antisera: rabbit 
anti-phosphoNR1 (recognizing phosphosphorylated Serine 897, 1/500, Upstate), rabbit anti-NR1 
(1/250, Epitomics), rabbit anti-GluR1 (1/2000, AbDSerotec), rabbit anti-GluR2/3 (1/250, 
Chemicon), rabbit anti-KA2, (1/1000, Millipore) and rabbit anti-GluR5 (1/1000, Novus). The 
antisera concentrations were determined after doing a series of dilution curves for each antibody 
on cornea, TG, and DRG. Tissues were incubated in primary antisera on a shaker at 4°C for 
120hr (Hoffman et al., 2010).  Tissues were rinsed three times in PBS, 10 minutes each and 
incubated in Alexafluor 488 conjugated goat anti-rabbit IgG (1/2000) for 60-90 minutes. Tissues 
were rinsed three times in PBS, 10 minutes each. Whole mounts were placed on glass slides.  
Coverslips were apposed using Prolong Gold mounting medium (Vector) and incubated overnight 
at room temperature.  Images were obtained using a Spot camera (Diagnostic Instruments) 
attached to an Olympus BX5I epifluorescence microscope. 
 
3.2.2 Retrograde tracing.  
Adult Sprague Dawley rats (n = 5) were anaesthetized with isofluorane, the eyelids were parted 
and 10µl of 5% Fluorogold was injected with a Hamilton syringe into the cornea using a 
dissecting microscope. The injection site was wipedimmediately with cotton tipped applicator and 
irrigated with distilled water.  Animals were allowed to recover from anesthesia before returning 
them to their cages. After 5 days, the animals were euthanized and transcardially perfused with 
fixative as described above. Ipsilateral trigeminal ganglia were rem
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10-20µm were processed for NR1, GluR1, KA2, and GluR5 immunoreactivity as described 
above. 
 
3.3 RESULTS 
On corneal whole mounts (Fig 3.1), there was intense NMDA pNR1 immunoreactivity on the 
corneal epithelial cell membrane and as scattered puntae within the nucleus. On sagittal sections 
(Fig. 3.2), NMDA NR1 immunoreactive (IR) varicose nerve fibers were identified that coursed 
through the corneal epithelium. 
 
GluR1 immunoreactivity was localized to the subepithelial corneal nerve plexus on corneal whole 
mount (Fig. 3.3). The nerve fibers were numerous and they had an extensive branching pattern. 
GluR2/3 immunoreactivity occurred in corneal epithelial cells within the cytoplasm and 
perinuclear area (Fig. 3.4). 
 
On whole mounts, corneal epithelial cells contained scattered KA2-IR granules in the cytoplasm 
(Fig. 3.5). 
 
Numerous neurons in the TG were identified with Fluorogold labeling (Fig. 3.6).  NR1 
immunoreactivity was localized to all retrogradely labeled neurons (Fig. 3.7), whereas KA2 and 
GluR5 immunoreactivity was only identified in small-medium diameter neurons (Hoffman et al., 
2010) that were retrogradely labeled (Fig. 3.8-3.9).  
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Figure3.1. NMDA pNR1 immunoreactivity in cornea (whole mount). Corneal epithelial cell 
membranes are immunoreactive for NMDA pNR 1 (white arrows) and as well as scattered pNR1 
immunoreactive granules within the nucleus (yellow arrows). 
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Figure3.2; NMDA NR1immunoreactivity in the rat cornea (10µm sagittal section). There was 
intense NMDA NR1 immunoreactivity on corneal epithelial nerve fibers (white arrows). These 
corneal afferent nerve fibers exhibited varicosities and traveled between the superficial corneal 
epithelial cells. 
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Figure3.3; AMPA GluR1 immunoreactivity in cornea (whole mount). Whole mount of the 
cornea shows GluR1 immunoreactivity on subepithelial plexus as indicated by the white arrows. 
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Figure3.4; AMPA GluR2/3 immunoreactivity in the rat cornea (10µm sagittal section). 
GluR2/3 immunoreactivity occurred in corneal epithelial cells. The distribution is mainly within 
the cytoplasm (white arrows) of the epithelial cells with a clustering around the nucleus (yellow 
arrows). 
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Figure3.5; Kainate KA2 immunohistochemistry in cornea (whole mount). There were 
numerous scattered immunoreactive granules in corneal epithelial cells for KA2 receptor subunit 
as indicated by the white arrows. 
  
  
 
Figure 3.6. Retrograde labeling of trigeminal neurons from cornea
into the cornea and, after five days, the trigeminal ganglion was processed for fluorescence 
microscopy. Numerous Fluorogold neurons, arrows point out examples, were retrogradely labeled 
from the cornea. 
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Figure3.7; Retrograde tracing study
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Figure 3.8; Retrograde tracing study
was localized to all retrogradely labeled neurons (arrows).
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Figure3.9; Retrograde tracing study
was localized to all retrogradely labeled neurons (arrows).
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3.4 DISCUSSION 
The present study demonstrates that NR1 (NMDA), GluR1 (AMPA), and GluR5 (kainate) EAAR 
subunits are present in corneal afferent nerves and/or corneal trigeminal neuronal cell bodies. 
These findings are consistent with previous studies that localized ionotropic EAARs to 
unmyelinated axons in the rat dermis (Carlton et al., 1995, Coggeshall et al., 1997, Coggeshall 
and Carlton, 1998, Du et al., 2003). For example, immunohistochemical studies localized EAAR 
subunits in rat sural and plantar nerves at the ultrastructural level: NMDA NR1 (21-30% of 
unmyelinated nerves), NR2B, GluR1 (8-17%), GluR2/3 and GluR5-7 (7-44%).  In the rat facial 
skin, most cutaneous afferents have NR2B immunoreactivity (Gazerani et al., 2010a), as well as 
muscle afferents in female rat temporalis muscle (Gazerani et al., 2010b). In the human hairy 
skin, unmyelinated axons (~25%) below the dermal–epidermal junction contain NR1, GluR 2/3, 
GluR5/6/7 immunoreactivity (Kinkelin et al., 2000), whereas afferents in human tendon contain 
NR1 immunoreactivity (Alfredson et al., 2001a).   
 
To our knowledge, this is the first demonstration of EAAR subunit immunoreactivity in nerve 
fibers among epithelial cells.  Corneal afferents are both unmyelinated and myelinated, but 
myelination is not maintained upon axonal entry into the cornea stroma for corneal transparency 
(Belmonte et al., 1997; Muller et al., 2003). Within the cornea, nerve bundles divide to form 
plexuses to supply the anterior corneal stroma and epithelium (Marfurt et al., 2001). Afferents 
form a subepithelial nerve plexus and corneal epithelial leashes, comprised of 2-6 axons, from the 
plexus innervate superficial corneal epithelial cells (Belmonte et al., 1997; Marfurt et al., 2001, 
Muller et al., 2003). The epithelial leashes are varicose fibers tangential to the corneal surface, 
parallel to one another, and terminate in the epithelium as free nerve endings (Marfurt et al., 
2001; Beckers et al., 1993). In the current study, NR1 and GluR1 immunoreactivity occurred in 
nerve fibers of the stroma, subepithelial plexus, leashes, and/or free nerve endings. Glutamate 
release in the cornea from epithelial cells or peripheral nerve terminals potentially could interact 
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with nearby nerve endings in either the stroma or the epithelium. 
 
Glutamate released in the cornea also could interact with corneal epithelial cells. In the current 
study, epithelial cells contained immunoreactivity for NR1 (NMDA), GluR2/3 (AMPA), and 
KA2 (kainate) EAAR subunits. Other investigators have identified EAAR subunits in cells in the 
stratum granulosum of the skin(Fischer et al., 2004b), buccal epithelium (Fischer et al., 2004a), 
olfactory epithelium (Borgmann-Winter et al., 2009) and renal tubular epithelium (Bozic et al., 
2011). Furthermore, there is evidence that glutamate is present in corneal epithelial cells 
(Langford et al., 2010).  Stimulation of EAARs on epithelial cells is thought to sensitize resident 
cells and surrounding afferents. It also has been shown that EAARs play a role in regulating 
calcium homeostasis in keratinocytes and calcium induced keratinocyte differentiation (Fischer et 
al., 2004a; Fischer et al., 2004b; Fischer et al., 2009). 
 
Glutamate is released peripherally from nociceptive afferent nerve terminals in response to high 
threshold stimuli in skin, joint, and muscle (Cairns et al., 2001; Du et al., 2001; Miller et al., 
2011a). Glutamate interacts with EAARs on peripheral afferent nerve terminals to cause 
nocifensive behavior and sensitization in both normal and inflamed tissues (Cairns et al., 2001; 
Du et al., 2001; Miller et al., 2011a).  Examples of EAAR that have been reported to produce 
sensitization in peripheral tissues include NMDA, AMPA and kainate receptors (Du et al., 2003; 
Du and Carlton, 2006; Miller et al., 2011a). The presence of glutamatergic nerve fibers (Miller et 
al., 2011b; Ibitokun – Chapter 2) and EAARs in rat cornea suggests that glutamate may have a 
similar effect in the cornea. The nocifensive role of EAARs in the rat cornea will be addressed in 
the next chapter. 
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CHAPTER 4 
 
IONOTROPIC GLUTAMATE RECEPTORS IN THE RAT CORNEA: BEHAVIORAL 
EVALUATION 
Aim: To determine the relative contribution of excitatory amino acid receptors (EAARs) on 
behavioral responses to glutamate, ionotropic EAAR receptor agonists, and EAAR antagonists. 
Methods: The number of cornea nocifensive or irritation behaviors (blinking, wiping and head 
shaking movements) were counted up to 30 seconds after instillation of increasing concentrations 
of: monosodium glutamate , NMDA (N-methyl-D-aspartate), AMPA (2-amino-3-(5-methyl-3-
oxo-1,2- oxazol-4-yl) propanoic acid) and kainate.  The effect of increasing concentrations of 
EAAR antagonists were determined on respective EAAR agonists, D-AP5 [D-(-)-2-Amino-5-
phosphonopentanoic acid, (NMDA antagonist)], NBQX [2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt, (AMPA antagonist)], and CNQX [6-
cyano-7-nitroquinoxaline-2,3-dione disodium, (AMPA/kainate antagonist)]. 
Results: Glutamate, AMPA and kainate independently induced corneal irritation behaviors in a 
dose dependent fashion.  The effects were blocked with complementary EAAR antagonists. 
NMDA did not induce significant nocifensive responses, however, D-AP5, NMDA antagonist, 
did produce a dose dependent inhibition of glutamate-induced behavior. 
Conclusion: These data indicate that EAARs can contribute to corneal irritation or nocifensive 
behavior.  Data also show that antagonism of corneal glutamate receptors can inhibit EAAR-
induced corneal irritation behavior.  EAARs may be important pharmacological targets for 
controlling corneal pain/irritation. 
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4.1 INTRODUCTION 
Glutamate is an excitatory neurotransmitter released from peripheral Aδ and C sensory nerve 
terminals (Miller et al., 2011a). The peripheral transport from trigeminal ganglion (TG) and 
dorsal root ganglion (DRG) neurons occurs in synaptic vesicles containing vesicular glutamate 
transporter 1 or 2 (VGLUT1/2; Aihara et al., 2000, Bellochio et al., 2000, Moechars et al., 2006, 
Brumovsky et al., 2007, Ibitokun, 2012 – Chapter 2).  Peripheral release of glutamate from 
nociceptive primary afferent nerve terminals in skin, muscle and joint occurs upon strong noxious 
stimulation. Glutamate released from peripheral nerve terminals exerts a sensitizing effect on 
surrounding afferents and resident cells and participates in the neurogenic inflammatory response 
(Cairns et al., 2001, Du and Carlton, 2006, Miller et al., 2011a). The effect of glutamate on the 
cornea, however, is not known.  
 
There is evidence that glutamate is present in human corneal superficial epithelial cells and 
stroma and in corneal afferents (Langford et al., 2010; Miller et al., 2011b). Substance P (SP) and 
calcitonin gene-related peptide (CGRP), neurotransmitters often co-released with glutamate, have 
been described in corneal primary afferent nerve fibers and terminals (Sasaoka et al., 1984, 
Beckers et al., 1993, Belmonte et al., 1997, Marfurt et al., 2001, Muller et al., 2003). We 
previously identified synaptic vesicle-related proteins, vesicular glutamate transporter 2 
(VGLUT2), synaptophysin I and SNAP 25 (synaptosomal associated protein 25), in nerve fibers 
of the rat cornea (Ibitokun – Chapter 2). These results indicated the potential release of glutamate 
from corneal primary afferent nerve terminals, similar to afferents in other peripheral tissues 
(Brumovsky et al., 2007; Miller et al., 2011a).  In addition, subunits of excitatory amino acid 
receptors (EAARs) have been identified immunohistochemically in corneal primary afferents and 
epithelial cells (Ibitokun, 2012 – Chapter 3).  Stimulation of EAARs in skin, joint, and muscle 
produces nocifensive behavior and pain responses in rodents and humans, respectively (Cairns et 
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al., 2001, Du and Carlton, 2006, Miller et al., 2011a).  The presence of corneal glutamate and 
EAARs suggests that similar events may occur from glutamatergic interactions in the cornea. To 
further understand the role of glutamate in the cornea, the present study aims at investigating the 
contribution of peripheral EAARs in cornea to irritative/nocifensive behavior. 
 
4.2 METHODS 
4.2.1 Animals 
All experiments were approved by the Oklahoma State University Animal Care and Use 
committee. A standardized corneal nociceptive animal model was employed to determine if 
stimulation of corneal glutamate receptors contribute to corneal irritation/nocifensive behavior 
(Gonzalez et al., 1993; Kárai et al., 2004; Bates et al., 2010). Adult Sprague Dawley rats (250 to 
450g) were used in all experiments. Rats were housed in groups of 2 to 3 in plastic cages with 
soft bedding under a 12-hour light/dark cycle. They had access to food and water ad libitum. 
Steps were taken to minimize the number of animals used and their discomfort. Some animals 
were used more than once in this study, but this only occurred 7 days after initial use. All corneal 
stimulations were limited to 30 sec and eyes were irrigated with water following stimulation.   
4.2.2 Dose response assay for EAAR agonists 
In order to detect nocifensive behavioral responses from EAAR stimulation, the following 
solutions were prepared: 1. monosodium glutamate (Sigma) - 0.01, 0.03, 0.1, 0.3, 0.5, 1.0M; 2. 
AMPA (2-amino-3-(5-methyl-3-oxo-1, 2- oxazol-4-yl) propanoic acid; (Tocris)) - 0.1, 0.3, 1.0, 
3.0, 10 mM; 3. Kainate (Sigma) - 0.001, 0.033, 0.1, 0.33, 1.0, 3.3 and 10 mM; 4. NMDA(N-
methyl-D-aspartate; (RBI)) - 0.1, 0.33, 1.0, 3.3, 10mM. The concentrations for the EAAR 
agonists were based on previous studies using other nociceptive tests in rodent skin, joints, and 
muscle (Miller et al., 2011a). The vehicle of instillation for glutamate, NMDA, AMPA and 
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kainate was phosphate buffered saline (PBS, pH = 7.4; (Carlton et al., 1995; Liu et al., 2002; Du 
et al., 2003; Du and Carlton, 2006; Miller et al., 2011a).  Each animal was removed from its cage, 
restrained by loosely wrapping it with a surgical towel and the eyelid was parted by hand. 
Monosodium glutamate, NMDA, AMPA or kainate solution was topically instilled (10µl) into the 
cornea (n=3-6/ treatment group). Rats were quickly removed from the towel and placed on top of 
a table with plexiglass walls for observation. The number of nocifensive/irritative behaviors, i.e., 
blinking, wiping, scratching, and head shaking movements, were counted up to 30 seconds after 
instillation and compared with animals that received only vehicle (Gonzalez et al., 1993, Karai et 
al., 2004, Bates et al., 2010).  
4.2.3 Antagonism of EAAR agonists 
In order to antagonize EAAR-agonist induced behavioral responses, the following solutions were 
prepared: 1. NBQX (2, 3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide 
disodium salt; AMPA antagonist; Tocris) - 0.033, 0.1, 0.33, 1 µg/µl; 2. CNQX (6-Cyano-7-
nitroquinoxaline-2,3-dione disodium salt; AMPA/kainate antagonist; Tocris) - 0.001, 0.01, 0.033, 
0.1, 0.33, 1 mM. The concentrations for the EAAR antagonists were based concentrations used in 
previous studies (Miller et al., 2011a).  The vehicle of instillation for CNQX was phosphate 
buffered saline (PBS, pH = 7.4; (Liu et al., 2002; Miller et al., 2011a) while PBS with 1% 
Dimethyl sulfoxide (DMSO) was the vehicle for NBQX (Lin et al., 1999; Miller et al., 2011a). 
Solutions were made in vehicle with or without their respective agonist: AMPA (0.1mM) or 
kainate (0.1mM). All the animals received their drugs by topical instillation into the cornea as 
described above. Animals in each group were pretreated with 10µl NBQX or CNQX alone. After 
10 minutes pretreatment with antagonist, animals were co-treated with 10µl of a mixture of 
AMPA/NBQX or kainate/CNQX solutions. The pretreatment concentrations of the antagonists 
were the same as the co-treatment concentrations. Agonist concentration was determined byED50 
or the minimum dose that induced corneal irritation on the dose response assay. Nocifensive 
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responses were counted up to 30 seconds after instillation. These responses were compared with 
animals that received only agonist or vehicle. 
4.2.4Antagonism of glutamate with D-AP5  
The NMDA receptor may be activated following AMPA and/or kainate receptor activation and 
membrane depolarization with glutamate, the endogenous neurotransmitter. In order to 
antagonize NMDA-related behavioral responses using glutamate, the following solutions were 
prepared: D-AP5 (D-(-)-2-amino-5-phosphonopentanoic acid; NMDA antagonist; Tocris) - 0.1, 
0.3, 1.0, 3.0 and 10µg/µl.  Solutions were made in vehicle with or without monosodium 
glutamate (0.5M). Animals were pretreated with 10µl D-AP5 alone and, after 10 minutes 
pretreatment, animals were co-treated with 10µl of a mixture of glutamate/AP5 solutions. 
Nocifensive behaviors were counted up to 30 seconds after instillation. These responses were 
compared with animals that received only agonist or vehicle. 
4.2.5 Data Analysis and Statistics 
Values were reported as means ± SEM.  Statistical significance was determined using one way 
ANOVA and Newman Keul’s post hoc multiple comparison test. P values ≤ 0.05 was considered 
as significant.  For comparison with glutamate response, data were converted into a percentage of 
maximal-minimal responses for determining dose response curves. A maximal behavioral 
response of 24 with glutamate stimulation was considered 100% and minimal vehicle response of 
1 was considered 0%.  All data were converted into a percentage of maximal-minimal responses 
for determining dose response curves (Miller et al., 2011b). Statistical tests were performed with 
GraphPad Prism software version 5.0 (San Diego, California USA).  
Maximum percent effect =    (Post drug latency – Baseline)   X 100 
                                                     Cut off – Baseline 
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 4.3 RESULTS 
4.3.1 Glutamate-induced corneal irritation 
Topical instillation of monosodium glutamate solution at 0.01-0.1M into intact rat cornea 
produced no significant behavioral responses compared to responses with vehicle.  Topical 
application of 0.3M glutamate was the first dose that produced the irritative behaviors of wiping, 
blinking, scratching, and head shaking and the behaviors peaked at 1.3M glutamate (Fig. 4.1.1, 
P≤ 0.05). The glutamate-induced behavior, therefore, occurred in a dose dependent fashion with 
an ED50 of 0.5M (Fig.4.2.1).  
4.3.2 AMPA-induced corneal irritation 
AMPA-induced corneal nocifensive behavior only occurred at the dose of 1.0mM AMPA (Fig. 
4.1.2; P≤ 0.05) and this was approximately 30% of the maximal response from glutamate (Fig. 
4.2.2). Lower (0.1-0.3mM) and higher (3-10mM) doses did not produce responses different from 
vehicle (Fig. 4.1.2). Curve fitting of the dose responses, therefore, produced an “inverted U-
shaped dose-effect curve” (IUSDEC; Fig. 4.1.2; (Baldi and Bucherelli, 2005). From the 0.1-
1.0mM dose response, an ED50 of 0.5mM for AMPA was determined.   
4.3.3 Kainate-induced corneal irritation 
Topical application of kainate induced corneal irritation only at the 1mM concentration (Fig. 
4.1.3, P≤ 0.05) and this was approximately 20% of the maximal response from glutamate (Fig. 
4.2.3). Lower (0.001-0.3mM) and higher (3-10mM) doses did not produce responses different 
from vehicle (Fig. 4.1.3).  As was observed with AMPA, curve fitting of kainate responses 
produced an IUSDEC (Fig. 4.1.3; (Baldi and Bucherelli, 2005). From the 0.001-1.0mM dose 
response, an ED50 of 0.1mM for kainate was determined. 
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4.3.4 NMDA-induced corneal irritation 
Instillation of the cornea with NMDA solutions in the concentration range of 0.1-10mM did not 
induce significant different nociceptive responses compared to vehicle (Fig. 4.1.4). 
4.3.5 Blockade of AMPA-induced corneal irritation 
To block AMPA induced stimulation, a fixed concentration of 1.0mM AMPA was used with 
varying concentrations of NBQX, a specific AMPA antagonist. At low concentration of 
0.033µg/µl NBQX, the nocifensive behavioral responses were not significantly different when 
compared with animals that received 1.0mM AMPA (Fig. 4.3.1).  At higher concentrations of 
0.1-1µg/µl, NBQX reduced the corneal irritation that was induced by 1.0M AMPA (Fig. 4.3.1; P≤ 
0.05). Antagonism dose response curves determined an ID50of 0.03µg/µl for NBQX inhibition of 
1.0mM AMPA (Fig. 4.4.1). 
4.3.6 Blockade of kainate-induced corneal irritation 
With the co-treatment of 0.1mM kainate and increasing concentrations of CNQX, kainate/AMPA 
antagonist, the nocifensive responses were significantly reduced in a dose dependent fashion (Fig. 
4.3.2). The highest concentrations of CNQX used in the study (0.033, 0.1, 0.33 and 1mM) 
reduced the kainate-induced responses (P≤ 0.05). Antagonism dose response curves determined 
an ID50of 0.02µg/µl for CNQX inhibition of 0.1mM kainate (Fig. 4.4.2). 
4.4.7 Blockade of glutamate-induced corneal irritation 
Glutamate activation of AMPA and kainate receptors depolarizes neuronal cellular membranes 
and this depolarization removes the Mg2+ block of NMDA receptors, allowing activation by 
glutamate (Nowak et al., 1984). To explore the role of NMDA receptors in glutamate-induced 
nociceptive behavior, NMDA antagonism with D-AP5 was used in conjunction with glutamate 
(0.5M).  Doses from 0.1-3.3µg/ml D-AP5 had no effect on glutamate, but 10µg/µl D-AP5 
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reduced glutamate induced corneal irritation (Fig. 4.3.3, P≤ 0.05). Antagonism dose response 
curves determined an ID50 of 3µg/µl for D-AP5 inhibition of 0.5M glutamate (Fig. 4.4.3). 
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Figure4.1 Nocifensive behavioral assay – EAAR agonists. Monosodium glutamate, AMPA and 
kainate (Fig. 4.1.1– 4.1.3) induced corneal irritation in a dose dependent fashion. NMDA did not 
produce significant behavioral responses (Fig. 4.1.4). * Indicates a significant difference, one way 
ANOVA. P < 0.05.n = 3-6 for each treatment group. 
  
 * 
** ** 
* 
* 
Fig. 4.1.1 Glutamate dose response study Fig. 4.1.2 AMPA dose response study 
response 
Fig. 4.1.3 Kainate dose response study Fig4.1.4 NMDA dose response study 
response 
*** 
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Fig 4.2.1 Glutamate dose response curve                  Fig 4.2.2 AMPA dose response curve  
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Fig 4.2.3 Kainate dose response curve 
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Figure 4.2. Agonist dose response curves. Fig. 4.2.1-4.2.4 are dose response curves for 
glutamate (Fig. 4.2.1), AMPA (Fig, 4.2.2) and kainate (Fig. 4.2.3). Glutamate, AMPA and 
kainate elicited significant nocifensive responses in a dose dependent fashion (ED50 = 0.5M, 
0.5mM and 0.1mM respectively). There was no significant response with NMDA.   
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Figure4.3.Nocifensive behavioral assay – EAAR antagonists. NBQX, AMPA antagonist, 
significantly blocked responses induced by AMPA in the cornea (Fig. 4.3.1).  In Fig 4.3.2, 
CNQX, kainate/AMPA antagonist, did not decrease responses significantly from 0.1mMkainate. 
D-AP5, NMDA antagonist, significantly blocked glutamate-induced nocifensive responses in a 
dose dependent fashion (Fig. 4.3.3).     (* Indicates a significant difference, one way ANOVA, P 
< 0.05. n = 3-6 for each treatment group.) 
* 
* 
Fig. 4.3.1 AMPA Inhibition with NBQX Fig. 4.3.2 Kainate Inhibition with CNQX 
Fig. 4.3.3 NMDA Inhibition with D-AP5 
* 
* 
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Fig 4.4.1 Antagonist inhibition curve of AMPA with NBQX 
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Fig 4.1.2 Antagonist inhibition curve of glutamate with D-AP5 
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Figure 4.4 Antagonist dose response curves. Fig. 4.4.1 is antagonist inhibition curve for 
inhibition of AMPA-induced nocifensive behavior. Fig. 4.4.2 is the antagonist inhibition curve 
for D-AP5, NMDA antagonist, exhibiting inhibition of glutamate-induced behavior. NBQX and 
AP5 significantly blocked AMPA and glutamate induced responses (ID50 = 0.03µg/µl and 3µg/µl, 
respectively). 
  
  
65 
Fig 4.5 Comparison of responses between EAAR in rat cornea 
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Figure 4.5; Comparison of responses to AMPA, kainate and glutamate in the cornea. AMPA 
and kainate have higher potency when compared with glutamate. Glutamate has a higher efficacy 
than AMPA and kainate in the cornea. 
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4.4 DISCUSSION 
Glutamate is the excitatory neurotransmitter used by primary sensory neurons.  In addition to 
release in the central nervous system, nociceptive afferents release glutamate from peripheral 
terminals in response to noxious or tissue damaging stimuli (Julius and Basbaum, 2001; Woolf 
and Ma, 2007; Miller et al., 2011a). Glutamate interacts with EAARs on peripheral terminals and 
excites the nociceptive afferents (Carlton et al., 1995; Du et al., 2001; Woolf and Ma, 2007; 
Miller et al., 2011a). This produces nocifensive responses and is perceived clinically as pain 
(Carlton et al., 1995; Du et al., 2001; Julius and Basbaum, 2001; Miller et al., 2011a). The present 
study demonstrated that topical instillation of glutamate, AMPA, and kainate into the cornea 
induces corneal irritation and nocifensive responses in a dose dependent manner. Findings in this 
study suggest that corneal glutamate receptors can play an important role in corneal nociception. 
These results are consistent with studies done in skin and muscle, where injection of glutamate 
and glutamate receptor agonists cause peripheral sensitization of primary afferents (Carlton et al., 
1995; Cairns et al., 2001; Du et al., 2003; Du and Carlton, 2006; Quinta˜o et al., 2010; Miller et 
al., 2011a).  
 
The findings in the current behavioral study corroborate data from our immunohistochemical 
study demonstrating that EAARs are present on corneal afferent nerves and epithelial cells. We 
also previously reported that glutamate and VGLUT2 is present in the rat corneal afferent nerves 
(Miller et al., 2011b; Ibitokun – Chapter 2). Additionally this is supported by studies localizing 
glutamate in superficial corneal epithelial cells and stroma (Langford et al., 2010). These 
observations from the current study further indicate that glutamate interacts with its receptors in 
the cornea to produce nociception. Furthermore, blockade of EAARs in rat cornea reduced 
EAAR-induced corneal irritation and nocifensive responses. This observation is consistent with 
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studies reporting that EAAR antagonists attenuate glutamate induced excitation in peripheral 
tissues (Carlton et al., 1995; Lin and Kinnamon, 1999; Peng et al., 2011; Miller et al., 2011a). 
 
4.4.1 Glutamate. A number of studies have evaluated the nocifensive responses to glutamate, 
EAAR agonists, and EAAR antagonists from the skin of rats and mice.  Injection of glutamate 
into the rat hindpaw or tail produces thermal hyperalgesia in the thermal plantar, hot water bath, 
and tailflick tests (Jackson et al., 1995; Carlton et al., 1998; Jin et al., 2009).  These responses are 
enantiomer selective, dose dependent, occur within minutes of injection, and last up to 4 hr 
(Jackson et al., 1995; Jin et al., 2009; Lin et al., 2009; Carlton et al., 1998).  Injection of 
intraplantar (i.pl.) glutamate into the rat hindpaw or subcutaneous (s.c.) injection into the rat tail 
produces mechanical hyperalgesia and allodynia in several behavioral tests, e.g., Randall-Selitto, 
plantar anesthesiometer, and von Frey filaments (Follenfant and Nakamura-Craig, 1992; Carlton 
et al., 1995; Coggeshall et al., 1997; Leem et al., 2001; Zanchet and Cury, 2003).  L-glutamate, 
but not D-glutamate, produces a dose dependent mechanical hyperalgesia (Follenfant and 
Nakamura-Craig, 1992; Carlton et al., 1995; Coggeshall et al., 1997; Walker et al., 2001).  The 
mechanical-evoked responses occur within minutes and can last up to 2 hr (Zanchet and Cury, 
2003; Leem et al., 2001; Carlton et al., 1995; Coggeshall et al., 1997).  Glutamate (i.pl. 0.01-
0.3mM) causes dose dependent mechanical hyperalgesia, but little to no response occurs at a 
higher dose of 1mM.  This has been interpreted to be due to desensitization of EAARs (Carlton et 
al., 1995; Coggeshall et al., 1997).  In the present study, glutamate caused dose-dependent 
behavioral responses, but we did not observe decrease in response at higher concentrations, up to 
1.3M glutamate. 
 
Mechanical and thermal tests evoked nocifensive responses from subcutaneous (s.c.) injections, 
whereas our study observed spontaneous irritative behaviors in response to topical application of 
glutamate.  In this regard, s.c. injection of glutamate evokes nocifensive responses or spontaneous 
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pain in rodents (Carlton et al., 1998; Lin et al., 2009; Beirith et al., 2002, 2003; Quintão et al., 
2010).  Spontaneous tail flicks occur when 5.0mM glutamate is co-administered s.c. with 
0.01mM Substance P (SP), but no response occurs with glutamate alone (Carlton et al., 1998).  In 
mice, i.pl. injection of glutamate produces dose dependent licking of the injected foot (Beirith et 
al., 2002; Lin et al., 2009).  Licking behavior occurs within 15 min and lasts 30 min (Beirith et 
al., 2002).  Also, there is evidence that injection (s.c.) of glutamate into the forehead of men and 
women elicits dose dependent pain and skin sensitization (Gazerani et al., 2006).  The pain is 
reported as moderate in intensity and lasts 5-10 min.  In addition, at high concentration (100mM, 
100µl), glutamate produces secondary hyperalgesia in humans (Gazerani et al., 2006).  Glutamate 
injection into the human masseter muscle causes dose dependent muscle pain perceptions for 5-
10 min that spreads to other areas, e.g., temporomandibular joint (TMJ), teeth, and temple (Cairns 
et al., 2001a,b, 2003; Wang et al., 2004; Svensson et al., 2003, 2005, 2008; Arendt-Nielsen et al., 
2008).  The present experimental design was constructed to evaluate the stimulation of EAARs in 
the corneal epithelium by topical instillation.  Most behavioral responses for glutamate and other 
EAAR agonists occurred within 15 sec following topical application, although nocifensive 
behavior was observed up to 30 sec.  Activation of EAARs on stromal afferents cannot be 
excluded in this design, but EAARs in the corneal epithelium most likely were the first to be 
activated.  Compared to other reports, response times in our study occurred quickly, but were of 
short duration.  S.c. injection of glutamate and EAAR agonists most likely produce a depot effect 
(Moll et al., 2004)causing longer responses than topical delivery.  Alternatively, the EAARs on 
corneal afferents or cells could desensitize quickly and behavioral responses, thereby, promptly 
curtailed.  Future studies should explore this issue, possibly with longer acting EAAR agonists, as 
well as determining if the corneal afferents have been sensitized with EAAR agonists.  This could 
be examined by using electrophysiological recording of ophthalmic afferents or with the use of 
evoked mechanical and thermal responses (Belmonte et al., 1997). 
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4.4.2 AMPA. I.pl. application of AMPA in rats dose-dependently produces thermal hyperalgesia 
within 15 min lasting for 3-4 hr (Jin et al., 2009). I.pl. AMPA-induced mechanical hyperalgesia 
occurs within 20 min and persists for 1hr (Zhou et al., 1996). In mice, i.pl. injection of AMPA 
produces mechanical hyperalgesia dose dependently, but with lower potency compared to 
glutamate (Walker et al., 2001).  Potency is the amount of drug that is required to produce an 
effect while efficacy is the maximal response that can be produced by a drug. In our study, 
AMPA was only 30% effective in eliciting nocifensive behavior compared to glutamate (Fig. 
4.5), although the concentration for AMPA’s response was 1.0mM compared to 1.0M for 
glutamate. Thus in the cornea, AMPA has a lower efficacy but higher potency when compared 
with glutamate.  
 
As with i.pl. injection of AMPA (Zhou et al., 1996), the maximal effect to i.pl. AMPA occurs at 
1mM with a sharp decrease in response at 3.0 and 10.0mM. This has been interpreted as 
desensitization of EAARs (Carlton et al., 1995; Zhou et al., 1996; Coggeshall et al., 1997; 
Gonzalez et al., 2010). Desenstization of AMPA and kainate receptors has best been studied in 
vitro from dissociated CNS neurons or expressed in immortalized cells (Dingledine et al., 1999; 
Gonzalez et al., 2010). It has been hypothesized that the AMPA receptor dimer interphase is not 
coupled together at rest. When AMPA binds to its receptor, a dimer interphase is formed and it 
stabilizes the open channel form of the receptor, i.e., the receptor is activated (Fig. 4.5). With 
continued exposure to AMPA, the dimer interphase decouples and the channel closes causing 
desensitization (Chaudhry et al., 2009; Gonzalez et al., 2010). The termination of ionotropic 
glutamate receptor response has also been explained in terms of ‘‘deactivation (loss of bound 
agonist) and desensitization (conversion into an unresponsive state)’’ (Mcfeeters and Oswald, 
2004). Desensitization of AMPA receptors is due to subunit composition and RNA splicing of 
AMPA receptor, e.g., the“flip/flop” region (Mcfeeters and Oswald, 2004). In the kainate receptor, 
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desensitization is due to differences in the amino acid residues of the subunits (Swanson et al., 
1997). 
  
  
 
Model of AMPA or 
 Agonist 
Diagram IX. Model of channel activation and desensitization in the presence of agonist in 
kainate and AMPA receptors
When agonist binds to the ligand binding domain, 
a conformational change occurs
desensitized state, there is decoupling of the ligand binding domain dimer interface due to 
mechanical stress (Swanson et al., 1997
even though the agonist is bound, the channel remains closed. The desensitized state is a lower 
energy state (Chaudhry et al., 2009).
 
Co-application of CNQX, AMPA/
mechanical hyperalgesia (Zhou et al., 1996)
glutamate can be blocked by i.pl. pretreatment (30 min) with NBQX (Beirith et al., 2002). In the 
current study, NBQX was used because it is specific for the AMPA receptor. Similar to effects 
71 
kainate receptor channel activation and desensitization 
in the presence of agonist 
. In the resting state, no agonist is bound and the channel is closed. 
a cleft in the ligand binding do
 leading to channel activation, i.e., channel open
; Mcfeeters and Oswald, 2004; Gonzalez et al., 2010
 
kainate antagonist, dose dependently blocks AMPA
. Spontaneous nocifensive responses caused by i.pl. 
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observed from s.c. injection of skin, pre- and co-treatment with NBQX dose dependently inhibits 
spontaneously evoked, corneal nocifensive responses. 
 
4.4.3 Kainate. Kainate injected s.c. causes mechanical hyperalgesia in rats.  Kainate s.c. causes a 
dose-dependent reduction in mechanical threshold within 20 min and lasting for 1 hr (Du et al., 
2006; Zhou et al., 1996). 1.0mM kainate produces a maximal response with a sharp decrease in 
response at 5mM). Potency is the amount of drug that is required to produce an effect while 
efficacy is the maximal response that can be produced by a drug. Our data reveals that a kainate 
concentration of 1mM induced significant nocifensive response, but it is only 20% of behavior 
elicited by glutamate (1.3M), (Fig 4.5). Thus in the cornea, kainate has a lower efficacy but 
higher potency when compared with glutamate. As with mechanical hyperalgesia, corneal 
nocicfensive responses at higher concentrations (3.3- 10mM showed a decline in behavioral 
responses observed, probably due to desensitization, as described earlier (Carlton et al., 1995; 
Cairns et al., 1998; Cairns et al., 2001). 
 
Co-application of CNQX with kainate dose dependently blocks the 1.0mM kainate induced 
mechanical hyperalgesia(Du et al., 2006; Zhou et al., 1996).  I.pl. glutamate induces paw licking 
in mice (Beirith et al., 2002) and pretreatment (30 min) with γ-D-glutamylaminomethyl sulfonic 
acid (GAMS; kainate antagonist; 0.1–3.0 mmol/20µl) decreases the nofensive responses (Zhou et 
al., 1993).Glutamate injected into the rat tail produces mechanical hyperalgesiathat is blocked by 
co-injection of CNQX (Zanchet and Cury, 2003). Inhibition of glutamate responses by CNQX 
could occur by interaction of AMPA, kainate, or both receptors. In our study, we used CNQX 
(kainate/AMPA receptor antagonist) to block responses induced by kainate. We found that 
CNQX (0.033-1µg/µl) produced no significant responses. This most likely is due to the kainate 
concentration that was used as it did not produce significant responses on the dose response 
study. 
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4.4.4 NMDA. Injection of NMDA s.c. dose-dependently produces thermal hyperalgesia in the rat 
hindpaw within 15 min lasting for 3-4 hr (Jin et al., 2009) and in the rat tail within 5 min lasting 
for over 2 hr (Lin et al., 2009).  I.pl. injection of NMDA produces mechanical hyperalgesia, 
butwith lower potency compared to glutamate (Walker et al., 2001).  I.pl. administration of 
NMDA produces dose dependent mechanical hyperalgesia within 20 min lasting for more than 1 
hr and mechanical allodynia for 30-40 min (Zhou et al., 1996).  Following i.pl.injection of 
NMDA, mice undergo licking the injected foot (Lin et al., 2009).  Unlike these previous studies 
with NMDA injection, NMDA did not produce any nocifensive behavior when instilled into the 
cornea. This may be due to the magnesium block of NMDA receptors, a lack of penetration of 
NMDA to access receptors, or the concentration used was too low for activation.     
 
Mechanical hyperalgesia induced by NMDA i.pl. administration is blocked by MK-801, NMDA 
antagonist (Zhou et al., 1996). Since NMDA at the doses used in the current study did not 
produce behavior responses, D-AP5 did not show an effect, but we did see an effect with 
glutamate-induce behavior. Previous studies had demonstrated that glutamate induced thermal 
hyperalgesia is inhibited by MK-801 or AP-7 co-administration (Carlton et al., 1998; Follenfant 
and Nakamura-Craig, 1992). Glutamate i.pl. produces mechanical hyperalgesia and this effect is 
attenuated by concurrent administration of MK-801 and AP5 (Zanchet and Cury, 2003; Carlton et 
al., 1998). Furthermore, i.pl. glutamate-induced paw licking in mice is inhibited by pretreatment 
with MK 801(Beirith et al., 2002).  When injected into the masseter muscle, 1.0M glutamate 
produces pain responses in human males, but co-injection of ketamine, NMDA antagonist, 
attenuates glutamate induced pain responses (Cairns et al., 2003). Ketamine reduces the peak 
response to glutamate as well as the overall amount of pain (Cairns et al., 2003).   
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Under resting membrane potential, the NMDA receptor is blocked by Mg2+ (Diagram VI), but 
depolarization causes phosphorylation of the NR1 subunit at the serine-896 site and release from 
the Mg2+block (Chen and Huang, 1992; Xiong et al., 1998; Lan et al., 2001). We did not observe 
pNR1 in corneal afferents, but did observe pNR1 immunoreactivity in epithelial cells. This would 
indicate that the Mg2+ block in corneal afferents is intact (Mayer and Westbrook, 1987, Monyer et 
al., 1994) and may be the reason for a lack of response to NMDA in the present study. We tested 
if D-AP5, NMDA antagonist, could block glutamate induced responses in the current study. We 
observed that pre- and co-instillation with DAP-5 blocked glutamate-induced nocifensive 
responses in a dose dependent fashion. This may indicate that glutamate activation of AMPA and 
kainate receptors lead to membrane depolarization and removal of the magnesium block of the 
NMDA receptor, and activation of the NMDA receptor (Mayer and Westbrook, 1987). As a result 
in the current, D-AP5 was able to have an antinociceptive effect. 
 
The observations from the current study indicate that EAARs can produce substantial irritative or 
nocifensive behaviors and inhibition of EAARs attenuates these responses. Future studies should 
be directed toward investigating EAARs under corneal inflammation or damage.  The results 
from the current and future studies may aid in the development of topical corneal pain relief by 
addressing EAAR activation and inhibition.  
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CHAPTER 5 
CONCLUSIONS 
Corneal nerves are often damaged and/or inflamed during accidental injuries, abrasions and 
penetration by foreign objects leading to ocular pain and discomfort. Ocular surgical procedures 
for correction of refractive errors, such as photorefractive keratectomy (PRK) and Laser in-situ 
Keratomileusis (LASIK) also have been implicated(Belmonte et al., 2003; Rosenthal et al., 2009). 
Likewise, infections such as herpes simplex keratitis or autoimmune disease like Sjrogren 
syndrome (Rosenthal et al., 2009) are known causes of ocular discomfort and pain. Uncontrolled 
corneal inflammation can impair corneal transparency and eventually lead to loss of vision.  
 
Steroids and non-steroidal anti-inflammatory drugs (NSAIDs) are analgesics of choice, but their 
use often is limited due to unwanted side effects like desquamation of corneal epithelial cells and 
corneal perforation (Kimura et al., 1962; Guidera et al., 2001). Local anesthetics are limited 
because of their short duration of action(Borsook and Rosenthal, 2011) and direct toxic effect on 
the cornea (Boljka et al., 1994). Opioids sometimes are used for ocular pain, but use is limited 
due to their addictive properties and other side effects, such as constipation and respiratory 
depression. Thus, long lasting management of corneal pain is a clinical need.  
 
In this study, the focus was on neurotransmitters, receptors and channels in nociceptors within the 
primary sensory neuron family. Since glutamate previously was demonstrated in superficial 
corneal epithelial cells and stroma (Langford et al., 2010) and glutamate is released peripherally 
from nociceptors in other tissues, the focus was on the mechanism of release of glutamate in the
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cornea, the presence of corneal excitatory amino acid receptors (EAARs, i.e., glutamate 
receptors) and the role of EAARs in the cornea. At the cellular level, synaptic vesicle proteins, 
vesicular glutamate transporters, and EAAR subunits were evaluated with immunolocalization 
techniques. Behavioral studies were performed to determine the role of specific EAARs in the 
cornea under basal conditions.  
 
In chapter 2, synaptophysin I (Fig. 2.3-2.4), VGLUT2 (Fig. 2.1 and 2.2) and SNAP25(Fig. 2.5) 
were evaluated with immunohistochemistry and Western blotting in rat cornea. Retrograde 
tracing from the cornea demonstrated that these proteins were from trigeminal ganglion neurons. 
Their presence in corneal sensory afferents, therefore, provides a cellular mechanism for release 
into the cornea via synaptic vesicles. In chapter 3, ionotropic EAAR subunits were detected with 
immunohistochemistry in the cornea. EAARs are expressed on corneal epithelial cells (pNR1; fig. 
3.1, GluR2/3; fig 3.4) and afferent nerve fibers in the cornea (NR1; fig 3.2, GluR1; fig 3.3, KA2;  
fig 3.5). Retrograde tracing from the cornea demonstrated that EAARs are expressed by corneal 
trigeminal ganglion neurons. Since studies in skin, muscle and joint show that glutamate interacts 
with its receptors to cause sensitization (Carlton et al., 1995; Cairns et al., 2001; Du et al., 2001; 
Du et al., 2003; Du and Carlton, 2006; Miller et al., 2011a), we hypothesized that glutamate in the 
cornea interacts with EAARs to cause irritation/nocifensive behavior. This issue was addressed in 
chapter 4. Glutamate (Fig. 4.1.1 and 4.2.1), AMPA (Fig 4.1.2 and 4.2.2) and kainate (Fig 4.1.3 
and 4.2.3) produced significant corneal irritative and nocifensive behavior in a dose dependent 
fashion. NMDA, however, did not elicit nocifensive behavior ( Fig. 4.1.4 and 4.2.4) possibly due 
to the magnesium block in the NMDA channel while cellular membranes are hyperpolarized. My 
study demonstrated that glutamate interacts with EAARs in the cornea to produce irritative and 
nocifensive behavior. Another important finding was that EAAR antagonists, NBQX (Fig. 4.3.1 
and 4.4.1) and AP5 (Fig. 4.3.3 and 4.4.3), were observed to attenuate corneal irritation caused by 
glutamate or respective glutamate receptor agonists. If corneal EAARs contribute to corneal 
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nociception and their antagonists can control glutamate induced pain, then EAARS may serve as 
an important pharmacological target for controlling corneal pain. Topical EAAR antagonists may 
help to control corneal irritation/pain, thereby circumventing possible CNS side effects, lessening 
systemic concentrations, and minimizing systemic side effects. 
 
 
 
 
 
 
  
 
 
Diagram X. Summary of study. This is an illustration of an afferent nerve terminal in 
the cornea. On application of noxious stimulus, glutamate is released into the cornea by 
synaptic vesicle exocytosis (Chapter 2). A stimulus at one nerve terminal may cause 
glutamate release from a collateral axonal terminal by way of the axonal reflex (Yaprak, 
2008). Released glutamate acts via its receptors on corneal epithelial cells and afferent 
nerve fibers in the cornea (Chapter 3) to sensitize resident corneal cells, the afferent nerve 
from where it is released, and surrounding afferent nerves (Chapter 4). Glu in the figure 
represent glutamate and dotted arrows represent the direction of glutamate action. 
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Future directions 
Although this study localized VGLUT2 and EAARs in the cornea (Chapter 2 and 3), it did not 
establish if they are up regulated during corneal inflammation as has demonstrated by studies 
done in the skin. Studies should be done to determine if expression of VGLUT2 in the cornea is 
augmented in sensory afferents during corneal inflammation. Also, this current study localized 
ionotropic EAARs in the rat cornea, but did not determine presence of metabotropic EAARs. If 
these receptors are present in the cornea, they may also contribute to corneal irritation/pain. A 
future direction will be to investigate for the expression of metabotropic glutamate receptors in rat 
cornea which may reveal more effective glutamate receptors leading to the possible development 
of more potent topical ocular analgesics. This study demonstrated that EAAR antagonists block 
glutamate-induced corneal irritation/pain (Chapter 4) in experimental animals under basal 
conditions. However, it does not represent how the antagonist might be used clinically because, 
as in any basic science research, interpretation of data in rats is subject to limitations, i.e., 
behavioral responses in rats are interpreted based on our perception of sensations in rats. 
Nevertheless, behavioral responses observed in rats are comparable to responses due to corneal 
irritation/pain in man such that our data may be translatable to humans. Thus, a future direction 
will be to formulate EAAR antagonists in ophthalmic solutions that can be topically instilled into 
the cornea during inflammation or before ocular surgeries. Electrophysiological studies should be 
done to explore the possibility of the use of longer acting EAAR agonists to desensitize corneal 
nerves. This is based on the finding that corneal afferent can easily be desensitized (Chapter 4). 
Further studies also should be done to determine if there is hyperalgesia after EAAR agonists are 
applied to the cornea.  
On antagonist studies, AMPA and kainate receptor antagonism of glutamate-induced nocifensive 
behavior should be further explored. Studies on corneal inflammation, quantitation of EAARs 
followed by behavioral responses to EAAR agonists and antagonists will generate useful 
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information on antagonist concentration that will be beneficial for pain relief. Ultrastructural 
studies will also give information on changes that occur to EAARs in the cornea during 
inflammation. Studies comparing varying concentrations of EAAR agonists with potency (IC50) 
of their corresponding antagonists should be pursued.(Zhou et al., 1996) 
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